Skip to search formSkip to main contentSkip to account menu

RP 56976

Known as: RP-56976 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Taxotere (TER) and tax01 (TA) are new antitumour agents currently undergoing clinical evaluation. We studied the antineoplastic… 
Highly Cited
1994
Highly Cited
1994
A multicenter phase I clinical trial of RP 56976 (docetaxel), a new anticancer drug, was performed with single and repeated doses… 
Highly Cited
1993
Highly Cited
1993
Taxotere (N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl Taxol; RP 56976; NSC 628503) is a semisynthetic analogue of Taxol. It is… 
Highly Cited
1993
Highly Cited
1993
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacytyl taxol (Taxotere, RP 56976) is a semisynthetic analogue of taxol, prepared from a… 
1993
1993
BACKGROUND The new cytostatic agent taxol has clearly demonstrated its effectiveness in ovarian cancer patients. The synthesis of… 
Highly Cited
1992
Highly Cited
1992
Highly Cited
1992
Highly Cited
1992
Taxotere (RP 56976, NSC 628503) is a new semisynthetic analog of taxol (NSC 125973) with promising antitumor activity in a… 
Highly Cited
1991
Highly Cited
1991
RP 56976 (taxotere), a new semisynthetic analogue of taxol, is a potentially important chemotherapeutic agent for the treatment… 
Highly Cited
1991
Highly Cited
1991
Taxotere (RP 56976; NSC 628503; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl taxol) is a new microtubule stabilizing agent. It…